Detalhe da pesquisa
1.
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Lancet
; 377(9759): 42-51, 2011 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21176949
2.
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
J Clin Oncol
; 30(9): 980-8, 2012 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22331940
3.
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
J Clin Oncol
; 28(10): 1756-65, 2010 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20194844
4.
Normalization of cytomegalovirus-specific CD4 T cells in HIV-1-infected individuals receiving antiretroviral therapy.
AIDS
; 16(7): 1075-7, 2002 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-11953477
5.
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Lancet Oncol
; 7(5): 379-91, 2006 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-16648042